Pine Bridge Investments, L.P. Nektar Therapeutics Transaction History

Pine Bridge Investments, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $4,785 - $10,264	-283 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $16,957 - $19,856	-547 Reduced 65.9%	283 $10,000
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $291,925 - $428,459	-9,244 Reduced 91.76%	830 $28,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $9,737 - $18,128	-320 Reduced 3.08%	10,074 $331,000
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $465,436 - $686,132	10,018 Added 2664.36%	10,394 $633,000

Q2 2018 Aug 09, 2018	SELL	$46.25 - $104.45 $8,417 - $19,009	-182 Reduced 32.62%	376 $18,000
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $7.41 Million - $14 Million	-129,034 Reduced 99.57%	558 $60,000
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $840,874 - $2.21 Million	36,528 Added 39.25%	129,592 $7.74 Million
Q3 2017 Nov 13, 2017	SELL	$17.79 - $24.0 $11,207 - $15,120	-630 Reduced 0.67%	93,064 $2.23 Million
Q2 2017 Aug 11, 2017	BUY	N/A	93,694	93,694 $1.83 Million

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Pine Bridge Investments, L.P., based on Form 13F filings with the SEC.

Stay updated on Pine Bridge Investments, L.P. with notifications on news.